StemCells Inc.

StemCells Inc. is engaged in the research and development of cell-based therapeutics. The company's proprietary HuCNS-SC cells (purified human neural stem cells) are currently in development as a potential treatment for a broad range of central nervous system disorders. The company is currently conducting phase 1/2 clinical trials in chronic spinal cord injury and dry age-related macular degeneration. StemCells Inc. is also pursuing preclinical studies in Alzheimer's disease, with support from the California Institute for Regenerative Medicine. The company markets stem cell research products, including media and reagents, under the SC Proven brand.

Expert Comments:

Jason Kolbert, Maxim Group (11/18/15)
"StemCells Inc. management will host a webcast to discuss the six-month interim results from the first cohort in its Phase 2 pathway study in cervical spinal cord injury; the company will also provide a progress update on the second 40-patient cohort that is currently enrolling patients. . .to our surprise, news came last week that Astellas Pharma Inc. announced plans to acquire cell therapy company Ocata Therapeutics Inc. for $379M. By every measure we use we see StemCells as a superior company, more clinically advanced. As such, we believe the Astellas acquisition sets a benchmark for valuation in the space."

"From my patient advocacy point of view, I've always been impressed with StemCells Inc. The company is in various areas of rare diseases and neurological disorders, such as Alzheimer's. This is a pioneering company dealing with the challenges of cell therapies. As an advocate for stem cell research, I am really impressed by its interaction with the patient community. Companies trying to move forward with cell therapies, gene therapies and other advanced therapies must find patients to enroll in clinical trials, and smart companies are very supportive of the patient advocacy movement. Patient advocacy comes from groups including the Juvenile Diabetes Research Foundation (JDRF), the Parkinson's Action Network, the Huntington's groups in California, the spinal cord injury community, and groups like Global Healthy Living Foundation, which runs the "CreakyJoints" Facebook site. Companies like StemCells Inc. are working with patient groups to understand needs and, in turn, hopefully provide potential treatments and cures. They have earned my respect." read more >

Katherine Genis, Edison Investment Research (9/1/15)
"StemCells Inc. has announced transplantation of the first patient in a recently initiated Phase 2 trial, evaluating its human central nervous system stem cells (HuCNS-SC) as a treatment for dry age-related macular degeneration. . .at a price of $0.41, the shares offer considerable potential, currently trading significantly below our risk-adjusted fair value of $1.82/share."

Ching-Yi Lin, H.C. Wainwright & Co. (8/7/15)
"Yesterday, StemCells Inc. reported Q2/15 earnings in-line with expectations. . .importantly, the company offered more detail on the disparate results of its Phase 1/2 dry age-related macular degeneration (dry AMD) program. . .management has included stricter criteria in its Phase 2 Radiant trial to ensure that only patients who have measurable geographic atrophy legions are enrolled. . .we reiterate our Buy rating and price target of $1.00."

Jason Kolbert, Maxim Group (8/7/15)
"StemCells Inc. ended Q2/15 with $30M cash, which should fund operations through multiple catalysts over the next year. The company's HuCNS-SC neural stem cells have advanced to two Phase 2 studies in both dry age-related macular degeneration (dry AMD) and cervical spinal cord injury (SCI). . .data from single-dose Phase 1/2 studies was positive, we’ll see as we wait for data from the large Phase 2 studies, which could come (SCI) later in 2015."

Edward Woo, Ascendiant Capital Markets (8/7/15)
"We remain positive on StemCells Inc. Despite recent stock volatility and weakness (likely due to its recent stock raise and mixed age-related macular degeneration (AMD) study results), we believe that the company represents an interesting investment story as it is progressing generally well in its clinical trials. . .we are maintaining our Buy rating but raising our 12-month price target to $1.75 from $1.50."

More Expert Comments

Experts Following This Company

Caroline Corner, Managing Director, Equity Research – Cantor Fitzgerald
Katherine Genis, Analyst – Edison Investment Research
Christopher James, Managing Director, Senior Equity Research Analyst – FBR Capital Markets
Jason Kolbert, Senior Analyst – Maxim Group
Ching-Yi Lin, Managing Director in Equity Research, Senior Biotech Analyst – H.C. Wainwright & Co.
Henry McCusker, Founder and Director of Research – Scimitar Equity
Bernard Siegel, Executive Director – Genetics Policy Institute
Edward Woo – Ascendiant Capital Markets

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.